Pathogenic Mechanisms of Disease in Idiopathic Inflammatory Myopathies: Autoantibodies As Clues

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Sep 16

PMID 39281689

Authors

Yuanhui Wu

Jiao Luo

Lihua Duan

Affiliations

Soon will be listed here.

Abstract

Idiopathic inflammatory myopathies (IIMs) encompass a spectrum of autoimmune diseases characterized by muscle inflammation and systemic involvement. This review aimed to synthesize current evidence on the clinical significance and pathogenic mechanisms underlying autoantibodies associated with IIMs. Autoantibodies targeting aminoacyl-tRNA synthetases (ARS) play a pivotal role in antisynthetase syndrome (ASS), highlighting associations with interstitial lung disease (ILD) and distinctive clinical features. Anti-Mi-2 antibodies in dermatomyositis (DM) are hallmarked by characteristic cutaneous manifestations and favorable prognostic outcomes. Conversely, anti-TIF1 antibodies are correlated with DM and a higher risk of malignancies, implicating CD8 T cells in its pathogenesis. Anti-MDA5 antibodies signify clinically amyopathic DM (CADM) with severe ILD, linked to dysregulated neutrophil extracellular trap (NET) formation. In immune-mediated necrotizing myopathies (IMNMs), anti-SRP and anti-HMGCR antibodies induce complement-mediated myopathy, typically following statin exposure. Additionally, anti-TRIM72 antibodies emerge as potential diagnostic markers in IIMs. Anti-cN1A autoantibodies are linked to inclusion body myositis (IBM) and play a decisive role in muscle protein degradation. Meanwhile, anti-FHL1 autoantibodies are associated with severe disease manifestations and muscle damage, as established in experimental models. Anti-eIF3 autoantibodies, recently identified in polymyositis (PM) patients, are rarely detected (<1%) and associated with a favorable prognosis. Elucidating these autoantibodies is anticipated to not only assist in early diagnosis and disease stratification but also inform targeted therapeutic interventions, emphasizing the intricate interplay between autoimmunity, cellular dysfunction, and clinical outcomes in IIMs.

References

Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M . MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol. 2008; 11(1):56-64. PMC: 2990407. DOI: 10.1038/ncb1812. View

Kao A, Lacomis D, Lucas M, Fertig N, Oddis C . Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004; 50(1):209-15. DOI: 10.1002/art.11484. View

Richards T, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico B . Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009; 60(7):2183-92. PMC: 2710404. DOI: 10.1002/art.24631. View

Tawara N, Yamashita S, Zhang X, Korogi M, Zhang Z, Doki T . Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. Ann Neurol. 2017; 81(4):512-525. DOI: 10.1002/ana.24919. View

Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T . RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009; 60(7):2193-200. DOI: 10.1002/art.24621. View

Cole R, Reddel S, Gervasio O, Phillips W . Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol. 2008; 63(6):782-9. DOI: 10.1002/ana.21371. View

Afzali A, Ruck T, Wiendl H, Meuth S . Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?. Autoimmun Rev. 2017; 16(5):478-494. DOI: 10.1016/j.autrev.2017.03.001. View

Allenbach Y, Keraen J, Bouvier A, Jooste V, Champtiaux N, Hervier B . High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016; 139(Pt 8):2131-5. DOI: 10.1093/brain/aww054. View

Uruha A, Nishikawa A, Tsuburaya R, Hamanaka K, Kuwana M, Watanabe Y . Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology. 2017; 88(5):493-500. DOI: 10.1212/WNL.0000000000003568. View

10.

Alshehri A, Choksi R, Bucelli R, Pestronk A . Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm. 2015; 2(4):e124. PMC: 4459046. DOI: 10.1212/NXI.0000000000000124. View

11.

Anquetil C, Boyer O, Wesner N, Benveniste O, Allenbach Y . Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmun Rev. 2019; 18(3):223-230. DOI: 10.1016/j.autrev.2018.09.008. View

12.

Nakashima R . Clinical significance of myositis-specific autoantibodies. Immunol Med. 2019; 41(3):103-112. DOI: 10.1080/25785826.2018.1531188. View

13.

Liu Y, Zheng Y, Hao H, Yuan Y . Narrative review of autoantibodies in idiopathic inflammatory myopathies. Ann Transl Med. 2023; 11(7):291. PMC: 10116429. DOI: 10.21037/atm-21-475. View

14.

Duvvuri B, Pachman L, Morgan G, Khojah A, Klein-Gitelman M, Curran M . Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis. Arthritis Rheumatol. 2019; 72(2):348-358. DOI: 10.1002/art.41078. View

15.

Herbert M, Stammen-Vogelzangs J, Verbeek M, Rietveld A, Lundberg I, Chinoy H . Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2015; 75(4):696-701. PMC: 4699257. DOI: 10.1136/annrheumdis-2014-206691. View

16.

Allenbach Y, Benveniste O . Peculiar clinicopathological features of immune-mediated necrotizing myopathies. Curr Opin Rheumatol. 2018; 30(6):655-663. DOI: 10.1097/BOR.0000000000000547. View

17.

Allenbach Y, Benveniste O, Goebel H, Stenzel W . Integrated classification of inflammatory myopathies. Neuropathol Appl Neurobiol. 2017; 43(1):62-81. DOI: 10.1111/nan.12380. View

18.

Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N . Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford). 2007; 46(6):1005-8. DOI: 10.1093/rheumatology/kem045. View

19.

Howard O, Dong H, Yang D, Raben N, Nagaraju K, Rosen A . Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002; 196(6):781-91. PMC: 2194054. DOI: 10.1084/jem.20020186. View

20.

Burd C, Kinyamu H, Miller F, Archer T . UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem. 2008; 283(50):34976-82. PMC: 2596409. DOI: 10.1074/jbc.M805383200. View